Investor Relations NASDAQ: MDWD Press Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 Date Title and Summary View Toggle SummaryMay 5, 2014 MediWound Announces Extraordinary General Meeting of Shareholders View HTML MediWound Announces Extraordinary General Meeting of Shareholders 15.9 KB Toggle SummaryMay 2, 2014 MediWound Reports First Quarter 2014 Financial Results View HTML MediWound Reports First Quarter 2014 Financial Results 35.4 KB Toggle SummaryMarch 25, 2014 MediWound Announces Closing of Initial Public Offering View HTML MediWound Announces Closing of Initial Public Offering 13.1 KB Toggle SummaryMarch 20, 2014 MediWound Prices Initial Public Offering View HTML MediWound Prices Initial Public Offering 11.5 KB Toggle SummarySeptember 23, 2012 Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ NexoBrid™ has shown statistically significant effect in earlier eschar removal from burn wounds and reduction in the number and extent of surgical excision and autografting View HTML Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ 13.9 KB Pagination First page First Previous page Previous … Page 15 Page 16 Page 17 Current page 18
Press Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 Date Title and Summary View Toggle SummaryMay 5, 2014 MediWound Announces Extraordinary General Meeting of Shareholders View HTML MediWound Announces Extraordinary General Meeting of Shareholders 15.9 KB Toggle SummaryMay 2, 2014 MediWound Reports First Quarter 2014 Financial Results View HTML MediWound Reports First Quarter 2014 Financial Results 35.4 KB Toggle SummaryMarch 25, 2014 MediWound Announces Closing of Initial Public Offering View HTML MediWound Announces Closing of Initial Public Offering 13.1 KB Toggle SummaryMarch 20, 2014 MediWound Prices Initial Public Offering View HTML MediWound Prices Initial Public Offering 11.5 KB Toggle SummarySeptember 23, 2012 Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ NexoBrid™ has shown statistically significant effect in earlier eschar removal from burn wounds and reduction in the number and extent of surgical excision and autografting View HTML Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ 13.9 KB Pagination First page First Previous page Previous … Page 15 Page 16 Page 17 Current page 18
Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™ 13.9 KB
